8-K: Codexis Reports Second Quarter 2024 Financial Results, Reaffirms Full-Year Guidance

Codexis announced its Q2 2024 financial results, reporting revenues in line with expectations and reiterating its full-year financial guidance, while also highlighting progress in its ECO Synthesis technology.

Summary

• Codexis announced its financial results for the second quarter of 2024, with total revenues of $8.0 million, compared to $21.3 million in the same quarter of 2023.
• Product revenues were $6.3 million, down from $11.0 million in Q2 2023, due to the timing of customer orders.
• R&D revenues decreased to $1.7 million from $10.3 million in Q2 2023, primarily due to lower non-recurring items.
• The company's product gross margin was 45%, a decrease from 71% in Q2 2023, due to variability in product mix.
• Codexis reported a net loss of $22.8 million, or $0.32 per share, compared to a net loss of $11.5 million, or $0.17 per share, in Q2 2023.
• The company reiterated its full-year 2024 financial guidance, expecting product revenues between $38 million and $42 million, excluding PAXLOVID related revenue, and R&D revenues between $18 million and $22 million.
• Codexis expects to enter its first technical collaboration for the ECO Synthesis manufacturing platform by the end of 2024.
• The company had $73.2 million in cash, cash equivalents, and short-term investments as of June 30, 2024, which is expected to fund operations through positive cash flow, anticipated around the end of 2026.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is reiterating guidance and making technical progress, the financial results show a significant decrease in revenue and an increase in net loss compared to the previous year. The company is also dependent on future collaborations and milestones.

Positives

• Codexis' revenues for the second quarter were in line with expectations.
• The company is on track to achieve double-digit year-over-year revenue growth.
• Technical progress with the ECO Synthesis platform has been faster than expected.
• Codexis has received a low-to-mid single-digit million-dollar order for its dsRNA ligase.
• The company has strengthened its commercial leadership with the appointment of Britton Jimenez as Senior Vice President, Commercial Operations.
• Codexis has finalized a purchase agreement for two gene therapy assets, which could lead to future revenue.
• The company has sufficient cash to fund operations through the end of 2026.

Negatives

• Total revenues for the second quarter of 2024 decreased significantly compared to the same period in 2023.
• Product revenues decreased due to the timing of customer orders.
• R&D revenues decreased due to lower non-recurring items.
• Product gross margin decreased due to variability in product mix.
• The company reported a larger net loss in Q2 2024 compared to Q2 2023.

Risks

• Codexis is dependent on its licensees and collaborators, and termination of these relationships could negatively impact the company.
• The company may need additional capital in the future to expand its business.
• There is a risk that Codexis may not be able to successfully develop new technologies, such as the ECO Synthesis platform and dsRNA ligase.
• Codexis is dependent on a limited number of products and customers, and adverse market reception of these products could harm the business.
• The company faces competition from other companies with greater resources and experience.
• Codexis must comply with debt covenants under its loan facility.
• Market and economic conditions may negatively impact the company's business, financial condition, and share price.

Future Outlook

Codexis anticipates entering its first technical collaboration for the ECO Synthesis manufacturing platform by the end of 2024 and expects to achieve positive cash flow around the end of 2026. The company has reiterated its full-year 2024 financial guidance.

Management Comments

• Stephen Dilly, MBBS, PhD, Chief Executive Officer at Codexis, stated that second quarter revenues were in line with expectations and that the company is on track to deliver double-digit year-over-year revenue growth.
• Management highlighted that technical progress has been faster than expected, particularly with the ECO Synthesis platform.
• Management noted that discussions with multiple potential partners are active and proceeding well.

Industry Context

The announcement highlights Codexis' progress in enzyme engineering and its focus on RNA therapeutics manufacturing, which is a growing area in the biotechnology industry. The company's ECO Synthesis platform and dsRNA ligase technology are aimed at improving the efficiency and cost-effectiveness of oligonucleotide synthesis, which is relevant to the broader trend of developing novel RNA-based therapies.

Comparison to Industry Standards

• Codexis' achievement of greater than 98% coupling efficiency in oligonucleotide synthesis is comparable to the industry standard achieved with phosphoramidite chemistry, which is a widely used method.
• The development of the ECO Synthesis platform and dsRNA ligase technology positions Codexis as a potential competitor to companies using traditional chemical synthesis methods for RNA therapeutics.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals are leaders in RNA therapeutics, and Codexis' technology could potentially be used by these companies or others in the field.
• The sale of gene therapy assets to Crosswalk Therapeutics is a common strategy for companies to focus on core competencies, similar to other biotech companies that divest non-core assets.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and increased net loss in Q2 2024.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Customers may benefit from the company's new technologies and services.
• Suppliers may be affected by changes in the company's operations and spending.
• Creditors may be monitoring the company's financial performance and ability to meet its obligations.

Next Steps

• Codexis will continue to develop its ECO Synthesis manufacturing platform.
• The company will work towards entering its first technical collaboration for the ECO Synthesis platform by the end of 2024.
• Codexis will complete the build-out of its ECO Synthesis Innovation Lab around the end of 2024.
• The company will focus on achieving its full-year 2024 financial guidance.
• Codexis will continue to explore opportunities for its dsRNA ligase technology.

Key Dates

Keywords

enzyme engineering, ECO Synthesis, RNA therapeutics, oligonucleotide synthesis, dsRNA ligase, financial results, biotherapeutics, pharmaceuticals, gene therapy, CodeEvolver